Zentalis PharmaceuticalsZNTL +0.10%30 Shareholder Yield % is -0.60% as of Mar. 2026. GuruFocus rates ZNTL with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,294 Biotechnology companies, Zentalis Pharmaceuticals ranks better than 54.71% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Zentalis Pharmaceuticals's Shareholder Yield % was -0.60%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Zentalis Pharmaceuticals Shareholder Yield % Related Terms
Zentalis Pharmaceuticals Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZNTL vs ELDN, GLSI, SABS: Shareholder Yield % Comparison
For the Biotechnology subindustry, Zentalis Pharmaceuticals's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zentalis Pharmaceuticals Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zentalis Pharmaceuticals's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Zentalis Pharmaceuticals's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Zentalis Pharmaceuticals (ZNTL) has a Shareholder Yield % of -0.60% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Zentalis Pharmaceuticals and its competitors. According to the industry distribution chart, Zentalis Pharmaceuticals ranks #586 out of 1294 companies in the Biotechnology industry, placing it in the top 45.3%.
Is Zentalis Pharmaceuticals' Shareholder Yield % too high?
Zentalis Pharmaceuticals' current Shareholder Yield % is -0.60%. Based on the distribution chart, Zentalis Pharmaceuticals ranks #586 out of 1294 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zentalis Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Zentalis Pharmaceuticals' Shareholder Yield % compare to ELDN and GLSI?
According to the Biotechnology industry distribution chart, Zentalis Pharmaceuticals ranks #586 out of 1294 companies for Shareholder Yield %. This puts Zentalis Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Zentalis Pharmaceuticals and its competitors. Zentalis Pharmaceuticals's current Shareholder Yield % is -0.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zentalis Pharmaceuticals stock overvalued right now?
Zentalis Pharmaceuticals (ZNTL) has a current Shareholder Yield % of -0.60%. The current Shareholder Yield % is -0.60%. Zentalis Pharmaceuticals' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Zentalis Pharmaceuticals (ZNTL), the current Shareholder Yield % is -0.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
30GF Score
Get the complete analysis for ZNTL
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZNTL has been successfully added to your 
